Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)

Solange Peters, Scott Gettinger, Melissa L. Johnson, +25

Journal of Clinical Oncology

Cloning of Transforming Growth Factor-β1 (TGF-β1) and Its Type II Receptor from Zebrafish Ovary and Role of TGF-β1 in Oocyte Maturation

Gurneet Kohli, Siqin Hu, Eric Clelland, +3

Endocrinology

Human GrowthZebrafish OvaryOocyte MaturationReproductive BiologyCell Growth +17

Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non–Small-Cell Lung Cancer

Martin Reck, Thomas Wehler, Francesco Orlandi, +16

Journal of Clinical Oncology

Managing Treatment–Related Adverse Events Associated with Alk Inhibitors

J. Rothenstein, Nathalie Letarte

Current Oncology

Adverse EventsAlk InhibitorsOncologyPharmacologyPathology +12

Company Stock Prices Before and After Public Announcements Related to Oncology Drugs

J. Rothenstein, George Tomlinson, Ian F. Tannock, +1

JNCI Journal of the National Cancer Institute

Real-World Benefit of Nivolumab in A Canadian Non-Small-Cell Lung Cancer Cohort

Rosalyn A. Juergens, Caroline Mariano, Jacques Jolivet, +11

Current Oncology

Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy

Penelope A. Bradbury, Donald G. Morris, Garth Nicholas, +21

Lung Cancer

Standard Salvage TherapyOncologyAdvanced Lung DiseaseClinical TrialsPathology +6

Canadian Consensus: Oligoprogressive, Pseudoprogressive, and Oligometastatic Non-Small-Cell Lung Cancer

Scott A. Laurie, Shantanu Banerji, Normand Blais, +15

Current Oncology

Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program

Oliver Illini, Maximilian J. Hochmair, Hannah Fabikan, +30

Therapeutic Advances in Medical Oncology

Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy

Miranda A. Moore, Sanjeev Gill, Timothy R. Asmis, +22

Annals of Oncology

Gastrointestinal OncologyMedicinePharmacologyColorectal CancerMetastatic Colorectal Cancer +8